美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

亞盛醫藥

25.70

-0.3100-1.19%

成交量：1,663.00

成交額：4.31萬

市值：23.99億

市盈率：-12.98

高：26.00

開：26.00

低：25.70

收：26.01

52周最高：48.45

52周最低：16.50

股本：9,333.04萬

流通股本：7,158.28萬

量比：0.74

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-1.9795

每股收益(LYR):-0.7356

淨資產收益率：-159.65%

總資產收益率：-22.77%

市淨率：25.06

市盈率(LYR):-34.94

資料載入中...

總覽公司新聞資訊公告

亞盛醫藥精彩亮相第44屆摩根大通醫療健康年會主會場，「全球創新」戰略邁入新階段

港股異動 | 亞盛醫藥-B(06855)漲近4% BTK降解劑APG-3288新藥臨牀申請獲美國FDA許可

亞盛醫藥BTK降解劑APG-3288的新藥臨牀申請（IND）獲美國FDA許可

亞盛醫藥-B(06855)：David Sidransky將獲委任為首席獨立非執行董事

中金:維持亞盛醫藥-B(06855)「跑贏行業」評級 POLARIS-1歐美獲批

【直擊2025 ASH】亞盛醫藥耐立克®治療TKI耐藥/不耐受CML-CP患者的註冊II期研究4年隨訪數據亮相，長期療效和安全性優勢再獲證實

【直擊2025 ASH】亞盛醫藥耐立克®二線治療CML-CP臨牀研究數據更新，更前線治療潛力明顯

【直擊2025 ASH】亞盛醫藥耐立克®治療初治Ph+ ALL患者註冊III期研究（POLARIS-1）數據國際首發，最佳MRD陰性完全緩解率超60%

亞盛醫藥的「底牌」

【直擊2025 ASH】亞盛醫藥Bcl-2抑制劑利生妥®治療維奈克拉經治髓系腫瘤患者的Ib/II期研究數據積極，全球競爭力持續顯現

【直擊2025 ASH】突破BTKi耐藥和複雜核型的困境！亞盛醫藥口頭報告利生妥®中國關鍵註冊研究數據

港股異動 | 亞盛醫藥-B(06855)升逾6% 耐立克®POLARIS-1研究獲美國FDA和歐洲EMA批准

亞盛醫藥-B(06855)耐立克®一線治療Ph+ ALL的全球註冊III期臨牀研究獲美國FDA和歐洲EMA批准

亞盛醫藥-B(06855)授出130.45萬份受限制股份單位及73.66萬份購股權

港股亞盛醫藥-B升逾3%

每日经济新闻

港股異動 | 亞盛醫藥-B(06855)升逾3% 首次揭示奧雷巴替尼通過調控脂質代謝發揮抗腫瘤作用全新機制

亞盛醫藥耐立克®胃腸道間質瘤領域研究進展在國際權威期刊《Signal Transduction and Targeted Therapy》發表

向新而行 | 生物科技新動能驅動產業變革與未來佈局

亞盛醫藥盤中異動早盤急速下跌7.00%

亞盛醫藥：Piper Sandler發布覆蓋評級，給予超配評級；目標價48美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AAPG/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":25.7,"timestamp":1769022492779,"preClose":26.01,"halted":0,"volume":1663,"delay":0,"changeRate":-0.011918492887351105,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"交易中","change":-0.31,"latestTime":"01-21 14:10:52 EST","open":26,"high":26,"low":25.7,"amount":43095.174908,"amplitude":0.011534,"askPrice":26,"askSize":503,"bidPrice":25.4,"bidSize":103,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1769029200000},"marketStatusCode":2,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":26.01,"preHourTrading":{"tag":"盘前","latestPrice":25.8,"preClose":26.01,"latestTime":"08:55 EST","volume":10,"amount":258,"timestamp":1769003752131,"change":-0.21,"changeRate":-0.008074,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":26.01,"preClose":26.01,"latestTime":"16:10 EST","volume":4,"amount":104.04,"timestamp":1768943404454,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.740433},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":0.740433,"shares":93330405,"dividePrice":0,"high":26,"amplitude":0.011534,"preClose":26.01,"low":25.7,"week52Low":16.5,"pbRate":"25.06","psRate":"42.73","week52High":48.45,"institutionHeld":0,"latestPrice":25.7,"committee":-0.660066,"eps":-1.979486,"divideRate":0,"volume":1663,"delay":0,"ttmEps":-1.979486,"open":26,"prevYearClose":26.24,"prevWeekClose":27.05,"prevMonthClose":26.24,"prevQuarterClose":26.24,"fiveDayClose":27.77,"twentyDayClose":29.31,"sixtyDayClose":34.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盤前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1764910800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2026-01-20","current":-12.983168,"percent":1,"low":-76.454813,"twenty":-45.982466,"median":-31.802125,"eighty":-19.05933,"high":-14.423092,"avg":-33.599274,"sd":16.13234,"marketCap":2402229436.35},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23},{"date":"2025-11-21","current":-17.547753,"twenty":-55.765092,"median":-33.408485,"eighty":-22.122489,"marketCap":2860955000.96},{"date":"2025-11-28","current":-18.539078,"twenty":-55.318442,"median":-33.361942,"eighty":-21.796498,"marketCap":3034915066.08},{"date":"2025-12-05","current":-18.33416,"twenty":-53.27811,"median":-33.187028,"eighty":-21.590149,"marketCap":3005486168.49},{"date":"2025-12-12","current":-17.062052,"twenty":-48.796704,"median":-32.920123,"eighty":-21.073758,"marketCap":2802301628.68},{"date":"2025-12-19","current":-16.188794,"twenty":-48.517949,"median":-32.72391,"eighty":-20.125041,"marketCap":2665447409.6},{"date":"2025-12-26","current":-15.347054,"twenty":-48.514967,"median":-32.664532,"eighty":-19.801335,"marketCap":2537308174.25},{"date":"2026-01-02","current":-14.520508,"twenty":-48.239817,"median":-32.57809,"eighty":-19.656119,"marketCap":2406972911.39},{"date":"2026-01-09","current":-15.636938,"twenty":-46.480698,"median":-32.420873,"eighty":-19.300607,"marketCap":2595562368.02},{"date":"2026-01-16","current":-14.792082,"twenty":-45.997596,"median":-31.846105,"eighty":-19.073232,"marketCap":2461528990.12},{"date":"2026-01-20","current":-14.423092,"twenty":-45.982466,"median":-31.802125,"eighty":-19.05933,"marketCap":2402229436.35}],"updateTime":1769022652081},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603621002","title":"亞盛醫藥精彩亮相第44屆摩根大通醫療健康年會主會場，「全球創新」戰略邁入新階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2603621002","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603621002?lang=zh_tw&edition=fundamental","pubTime":"2026-01-15 09:16","pubTimestamp":1768439760,"startTime":"0","endTime":"0","summary":"2025年是亚盛医药全球化布局提速的关键一年，我们在产品商业化、全球临床开发、管线创新、资本市场等多维度均实现跨越式突破。展望2026年，'全球创新'战略迈入新阶段，我们将继续以解决全球未满足的临床需求为核心，加速推进这些极具潜力的创新疗法，更好地惠及全球患者。在以患者为中心的全球创新战","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4864009_ZH64009_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00BN8TJ469.HKD","LU0345770308.USD","LU2211815571.USD","LU0215105999.USD","BK4533","LU0267386448.USD","LU2106854487.HKD","LU2237443895.HKD","IE00BKDWB100.SGD","LU1894683348.USD","BK4585","LU0345770993.USD","LU0640476718.USD","LU0689472784.USD","06855","LU0820561818.USD","LU2756315318.SGD","XBI","LU1551013425.SGD","LU0170899867.USD","IE00BKVL7J92.USD","LU0265550946.USD","LU0208291251.USD","XLV","IE0034235303.USD","LU0106261372.USD","LU1629891620.HKD","SG9999002224.SGD","IE00BLSP4452.SGD","LU2746668974.SGD","LU2756315664.SGD","LU0211328371.USD","LU1974910355.USD","LU0417517546.SGD","BK4516","LU2381873111.SGD","LU0345769631.USD","LABU","IE00BJLML261.HKD","LU1668664300.SGD","LU1720051017.SGD","AAPG","LU1914381329.SGD","LU0868494617.USD","LU1280957306.USD","IE00BJTD4N35.SGD","LU1496350171.SGD","LU0942090050.USD","LU2592432038.USD","LU1267930490.SGD"],"gpt_icon":0},{"id":"2601828013","title":"港股異動 | 亞盛醫藥-B(06855)漲近4% BTK降解劑APG-3288新藥臨牀申請獲美國FDA許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828013","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601828013?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 10:39","pubTimestamp":1767753579,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B(06855)涨近4%，截至发稿，涨3.69%，报53.4港元，成交额6164.18万港元。消息面上，1月7日，亚盛医药官微消息，公司宣布，原创新一代BTK靶向蛋白降解剂 APG-3288的新药临床申请(IND)已获美国FDA许可，将开展其治疗复发/难治B细胞恶性肿瘤的临床研究。这标志着公司在靶向蛋白降解领域的研发成果正式进入临床阶段，是亚盛医药全球创新管线的又一重大布局。该研究是一项全球多中心、开放性的I期临床研究，旨在评估APG-3288治疗复发/难治性血液系统恶性肿瘤患者的安全性、耐受性、PK特征及初步疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","LU2125909916.SGD","APG","LU1923622291.USD","BK1574","AAPG","BK4129","LU2125909759.SGD","BK1161","06855"],"gpt_icon":0},{"id":"2601824845","title":"亞盛醫藥BTK降解劑APG-3288的新藥臨牀申請（IND）獲美國FDA許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2601824845","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601824845?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 09:30","pubTimestamp":1767749400,"startTime":"0","endTime":"0","summary":"临床前研究结果显示，与其他在研BTK降解剂相比，APG-3288具更强的BTK降解能力、更高的选择性及更优越的PK特征，呈现潜力5。此次APG-3288的IND获美国FDA许可，是我们在这一领域的重大里程碑。我们将快速推进APG-3288的全球临床开发，积极探索蛋白降解剂这一新分子实体在血液肿瘤及其他BTK相关疾病中的治疗潜力，早日惠及更多患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4858031_ZH58031_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4129","APG","BK1574","LU2125909759.SGD","IND","TK","AAPG","BK1161","BK4139","BK4144","06855","LU1923622291.USD","LU2125909916.SGD"],"gpt_icon":0},{"id":"2595713529","title":"亞盛醫藥-B(06855)：David Sidransky將獲委任為首席獨立非執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2595713529","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595713529?lang=zh_tw&edition=fundamental","pubTime":"2025-12-30 22:47","pubTimestamp":1767106065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，Debra Yu博士将获委任为董事会提名委员会新增成员，自2025年12月26日起生效。David Sidransky博士将获委任为首席独立非执行董事，自2025年12月26日起生效，以作为其他董事与本公司股东之间的中间人;及在与董事会主席或本公司管理层的正常沟通渠道不足的情况下，可与其他董事及本公司股东联络。研发委员会将由Marc E. Lippman, MD博士担任主席，由David Sidransky博士及王少萌博士担任成员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06855","BK1574","BK4139","AAPG"],"gpt_icon":0},{"id":"2592466968","title":"中金:維持亞盛醫藥-B(06855)「跑贏行業」評級 POLARIS-1歐美獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2592466968","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592466968?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 11:38","pubTimestamp":1765942705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持亚盛医药-B“跑赢行业”评级与目标价89港元，公司近期研发进展积极。耐立克一线治疗Ph+ ALL的全球III期研究已获欧美药监机构批准开展，并公布亮眼初步数据；利生妥针对高危基线人群亦显示出良好疗效与安全性，整体研发管线持续兑现，国际化稳步推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","06855"],"gpt_icon":0},{"id":"2590316821","title":"【直擊2025 ASH】亞盛醫藥耐立克®治療TKI耐藥/不耐受CML-CP患者的註冊II期研究4年隨訪數據亮相，長期療效和安全性優勢再獲證實","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316821","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590316821?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 09:45","pubTimestamp":1765244700,"startTime":"0","endTime":"0","summary":"此次展示的4年随访数据显示，耐立克在TKI耐药/不耐受的CML-CP患者中，持续展现出优于研究者决定的现有最佳可用疗法的显著疗效。值得关注的是，长期随访数据证实其安全性良好，血管闭塞事件发生率为7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842158_ZH42158_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","ASH","BK4139","06855","BK4109","BK4585","BK1574","AAPG","BK4016","BK4588","CP","LU1261432733.SGD","LU2463526074.USD"],"gpt_icon":0},{"id":"2590316824","title":"【直擊2025 ASH】亞盛醫藥耐立克®二線治療CML-CP臨牀研究數據更新，更前線治療潛力明顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316824","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590316824?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 09:34","pubTimestamp":1765244040,"startTime":"0","endTime":"0","summary":"此次公布是对该研究在2024 ASH年会口头报告结果的持续更新，展现了更长时间的随访疗效与安全性特征。此次更新的研究结果进一步提示耐立克有望为二线CML-CP患者带来一种安全有效的治疗选择，尤其对那些一线使用二代BCR-ABL1酪氨酸激酶抑制剂治疗失败的患者。此次数据的更新，进一步体现了耐立克为更广泛的CML患者群体提供安全有效治疗选择的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842159_ZH42159_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2463526074.USD","BK1161","BK4016","LU1261432733.SGD","AAPG","BK4585","06855","ASH","BK4588","BK1574","CP","BK4139","BK4109"],"gpt_icon":0},{"id":"2590316827","title":"【直擊2025 ASH】亞盛醫藥耐立克®治療初治Ph+ ALL患者註冊III期研究（POLARIS-1）數據國際首發， 最佳MRD陰性完全緩解率超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316827","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590316827?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 09:22","pubTimestamp":1765243320,"startTime":"0","endTime":"0","summary":"此次展示的POLARIS-1研究数据体现了耐立克在Ph+ ALL治疗领域的巨大潜力。数据显示，在诱导治疗3个周期内，耐立克联合低强度化疗在初治Ph+ ALL患者中的最佳微小残留病阴性率和MRD阴性完全缓解率分别为66.0%和64.2%；同时显示出良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842157_ZH42157_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1699723380.USD","LU2355687059.USD","BK4533","LU0985320562.USD","BK1574","BK1161","ALL","BK4134","BK4109","06855","BK4588","BK4139","III","AAPG","BK4585","ASH","BK4107","LU2463526074.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"2590236472","title":"亞盛醫藥的「底牌」","url":"https://stock-news.laohu8.com/highlight/detail?id=2590236472","media":"药渡Daily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590236472?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 18:11","pubTimestamp":1765188681,"startTime":"0","endTime":"0","summary":"两大王牌产品的成功，成为亚盛医药快速成长的核心“底牌”。从血液肿瘤到实体瘤，从中国市场到全球舞台，亚盛医药更大的“底牌”正在翻开。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208214536a43b9611&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208214536a43b9611&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK4139","AAPG","ASPHF"],"gpt_icon":0},{"id":"2589848384","title":"【直擊2025 ASH】亞盛醫藥Bcl-2抑制劑利生妥®治療維奈克拉經治髓系腫瘤患者的Ib/II期研究數據積極，全球競爭力持續顯現","url":"https://stock-news.laohu8.com/highlight/detail?id=2589848384","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589848384?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 09:58","pubTimestamp":1765159080,"startTime":"0","endTime":"0","summary":"此次数据进一步验证了利生妥在恶性髓系肿瘤领域所具备的稳健疗效与良好安全性。利生妥是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。期待利生妥在未来，能为髓系恶性肿瘤治疗领域带来新的突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4841048_ZH41048_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","AAPG","BK1574","06855","BK4139","LU2463526074.USD","ASH","BK4109"],"gpt_icon":0},{"id":"2589487292","title":"【直擊2025 ASH】突破BTKi耐藥和複雜核型的困境！亞盛醫藥口頭報告利生妥®中國關鍵註冊研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2589487292","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589487292?lang=zh_tw&edition=fundamental","pubTime":"2025-12-07 17:11","pubTimestamp":1765098660,"startTime":"0","endTime":"0","summary":"此项关键研究支持了利生妥于2025年7月获中国国家药品监督管理局批准上市。ASH年会是全球血液学领域规模最大的国际学术盛会之一，汇集了最前沿的研究进展及最新的药物研发数据，展示全球血液学领域的最高学术水平。目前，该药物已在中国获批上市，用于既往经过至少包含BTKi在内的一种系统治疗的成人CLL/SLL患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4840909_ZH40909_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","BK1161","LU2463526074.USD","BK4109","06855","BK4139","ASH","AAPG"],"gpt_icon":0},{"id":"2589519008","title":"港股異動 | 亞盛醫藥-B(06855)升逾6% 耐立克®POLARIS-1研究獲美國FDA和歐洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589519008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589519008?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 09:33","pubTimestamp":1764898401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超6%，截至发稿，涨5.67%，报64.2港元，成交额1993.31万港元。消息面上，12月5日，亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。作为耐立克在欧美监管机构获批的第二个全球注册III期研究，POLARIS-1研究在多国家多中心同步入组，将加速耐立克全球特别是欧美市场的上市进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06855","BK4139","BK1161","EMA","BK4081","AAPG"],"gpt_icon":0},{"id":"2589985521","title":"亞盛醫藥-B(06855)耐立克®一線治療Ph+ ALL的全球註冊III期臨牀研究獲美國FDA和歐洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589985521","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589985521?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 08:03","pubTimestamp":1764893004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。同时，耐立克在Ph+ ALL领域深度布局，针对Ph+ ALL领域的治疗已获《CSCO恶性血液病诊疗指南》连续推荐，并获CDE突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4081","06855","BK1574","BK1161","BK4139","BK4585","BK4588","BK4107","BK4134","BK4533","EMA","LU1571399168.USD","LU2355687059.USD","LU1699723380.USD","III","AAPG","ALL","LU0985320562.USD"],"gpt_icon":0},{"id":"2586467228","title":"亞盛醫藥-B(06855)授出130.45萬份受限制股份單位及73.66萬份購股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2586467228","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586467228?lang=zh_tw&edition=fundamental","pubTime":"2025-11-27 21:18","pubTimestamp":1764249535,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，截至本公告日期，已根据2022年受限制股份单位计划向2022年受限制股份单位计划的146名获选人士授出130.45万份受限制股份单位，相当于130.45万股股份(2022年进一步授出)。截至本公告日期，公司根据首次公开发售后购股权计划条款向34名获授人授出合共73.66万份购股权，可于行使有关购股权时认购合共73.66万股公司普通股，惟须待购股权获授人接纳后方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","06855","AAPG","BK4139"],"gpt_icon":0},{"id":"2586284951","title":"港股亞盛醫藥-B升逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586284951","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586284951?lang=zh_tw&edition=fundamental","pubTime":"2025-11-26 11:03","pubTimestamp":1764126180,"startTime":"0","endTime":"0","summary":"每经AI快讯，亚盛医药-B(06855.HK)涨超3%，截至发稿，涨3.04%，报64.35港元，成交额4604.84万港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-11-26/doc-infysxme3338276.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-26/doc-infysxme3338276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK4139","BK1161","AAPG","06855"],"gpt_icon":0},{"id":"2586281468","title":"港股異動 | 亞盛醫藥-B(06855)升逾3% 首次揭示奧雷巴替尼通過調控脂質代謝發揮抗腫瘤作用全新機制","url":"https://stock-news.laohu8.com/highlight/detail?id=2586281468","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586281468?lang=zh_tw&edition=fundamental","pubTime":"2025-11-26 10:47","pubTimestamp":1764125279,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超3%，截至发稿，涨3.04%，报64.35港元，成交额4604.84万港元。研究结果表明奥雷巴替尼在琥珀酸脱氢酶缺陷型GIST中具有良好的疗效与安全性，并首次揭示奥雷巴替尼通过调控脂质代谢发挥抗肿瘤作用的全新机制。据悉，这是迄今为止针对该罕见GIST亚型规模最大的前瞻性临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","06855","AAPG","BK1574","BK1161"],"gpt_icon":0},{"id":"2586044224","title":"亞盛醫藥耐立克®胃腸道間質瘤領域研究進展在國際權威期刊《Signal Transduction and Targeted Therapy》發表","url":"https://stock-news.laohu8.com/highlight/detail?id=2586044224","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586044224?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 10:34","pubTimestamp":1764038040,"startTime":"0","endTime":"0","summary":"《信号转导与靶向治疗》是国际知名权威期刊，隶属于《自然》出版集团。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4832671_ZH32671_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06855","BK1161","BK4139","AAPG","BK1574"],"gpt_icon":0},{"id":"2585176023","title":"向新而行 | 生物科技新動能驅動產業變革與未來佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2585176023","media":"南方基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585176023?lang=zh_tw&edition=fundamental","pubTime":"2025-11-22 13:11","pubTimestamp":1763788269,"startTime":"0","endTime":"0","summary":"实验室的光点亮创新的方向政策的风吹起医药产业的帆扬当新质生产力渗入制药方程中国生物科技，正书写新的篇章把握医药行业“向新而行，以质致远”的发展图景，需要洞察其深层动力：揭示中国生物科技跻身全球第一梯队的路径与产业链韧性成因，解读生物科技企业发展的核心驱动逻辑，并前瞻中药、创新器械等关键赛道的未来机遇。03政策、体系、人才三重驱动，支持生物科技企业中国生物科技企业崛起，依托三大关键支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251122131246a4b2f4ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251122131246a4b2f4ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06855","06978","AAPG"],"gpt_icon":0},{"id":"2584327965","title":"亞盛醫藥盤中異動 早盤急速下跌7.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584327965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584327965?lang=zh_tw&edition=fundamental","pubTime":"2025-11-19 00:00","pubTimestamp":1763481637,"startTime":"0","endTime":"0","summary":"北京时间2025年11月19日00时00分，亚盛医药股票出现异动，股价大幅跳水7.00%。截至发稿，该股报30.42美元/股，成交量594股，换手率0.00%，振幅0.52%。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。亚盛医药股票所在的生物技术行业中，整体跌幅为0.33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119000037a70249a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119000037a70249a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","06855","BK4139"],"gpt_icon":0},{"id":"1163861320","title":"亞盛醫藥：Piper Sandler發布覆蓋評級，給予超配評級；目標價48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163861320","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163861320?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 17:03","pubTimestamp":1762333390,"startTime":"0","endTime":"0","summary":"亚盛医药：Piper Sandler发布覆盖评级，给予超配评级；目标价48美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1161","06855","AAPG","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":71,"code":"91000000","status":"200"}]}}